Investigating a new treatment to improve insulin sensitivity in patients with severe lipodystrophy
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
This study is testing a new treatment called TLC-1235 to see if it can help people with severe lipodystrophy by improving how their bodies use fat for energy and reducing insulin resistance, and if you join, you could be among the first to try it out!
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orsobio, INC. NIH-funded |
| Lab location | 1 site (Menlo Park, UNITED STATES) |
| Project ID | NIH-10925338 on NIH RePORTER |
What this research studies
This research focuses on TLC-1235, a controlled-release mitochondrial protonophore designed to help patients with severe lipodystrophy, a condition that leads to insulin resistance and other metabolic issues. The approach involves using this compound to enhance the oxidation of fatty acids in the mitochondria, which may help reduce harmful lipid accumulation in the body. By improving cellular energy regulation and decreasing reactive oxygen species, this treatment aims to reverse insulin resistance and improve overall metabolic health. Patients participating in this research may receive this novel therapy and contribute to understanding its effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with severe lipodystrophy who experience significant insulin resistance and related complications.
Not a fit: Patients without severe lipodystrophy or those who do not exhibit insulin resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from severe lipodystrophy and related metabolic disorders.
How similar studies have performed: While the use of mitochondrial protonophores is a novel approach, similar strategies targeting lipid metabolism have shown promise in other research contexts.
Where this research is happening
Menlo Park, UNITED STATES
- Orsobio, INC. — Menlo Park, United States (Active)
Researchers
- Principal investigator: Myers, Robert Paul — Orsobio, INC.
- Study coordinator: Myers, Robert Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.